UCB - Operating Expenses


UCB reported EUR2.96B in Operating Expenses for its fiscal semester ending in December of 2025.





Operating Expenses Change Date
Alcon AG USD 2.78B 370M Jun/2026
Almirall EUR 531.16M 13.76M Jun/2026
Amarin USD 51.48M 113K Dec/2025
argenx SE USD 1.24B 213M Sep/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bayer EUR 10.04B 168M Jun/2026
Genmab DKK 748M 77M Jun/2026
GlaxoSmithKline GBP 5.8B 468M Jun/2026
GRIFOLS EUR 1.55B 94M Jun/2026
Hikma Pharmaceutical USD 1.34B 702M Dec/2025
Lakefront Biotherapeutics EUR 55.62M 14.56M Jun/2026
Lonza CHF 2.9B 184M Jun/2025
Merck EUR 4.34B 249M Jun/2026
Novartis USD 10.2B 912M Jun/2026
Orion EUR 345M 42.1M Jun/2026
Recordati EUR 493.59M 11.28M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
Sanofi EUR 9.92B 607M Jun/2026
UCB EUR 2.96B 196M Dec/2025
Unibail Rodamco EUR 646.6M 25.4M Dec/2025